共 124 条
[1]
Einarson TR(2018)Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 Cardiovasc Diabetol 17 83-657
[2]
Acs A(2017)Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes N Engl J Med 377 644-2306
[3]
Ludwig C(2019)Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 380 2295-357
[4]
Panton UH(2019)Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med 380 347-2128
[5]
Neal B(2015)Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes N Engl J Med 373 2117-39
[6]
Perkovic V(2019)SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Lancet 393 31-1591
[7]
Mahaffey KW(2018)Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis JAMA 319 1580-2701
[8]
Perkovic V(2019)GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis PLoS One 14 e0217701-323
[9]
Jardine MJ(2019)Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis Cardiovasc Diabetol 18 112-168
[10]
Neal B(2018)Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 41 2669-1904